Your browser does not support JavaScript!
吳治慶副教授

 (Chih-Ching Wu)

學歷

長庚大學生物醫學研究所博士

任課科目

生物化學、臨床生物化學

研究專長

蛋白質體學、系統生物學、腫瘤生物學

辦公室分機

5093

實驗室分機

3562

個人網頁

臨床蛋白質體學研究室

E-mail

luckywu@mail.cgu.edu.tw

研究方向及研究室特色(Lab & Research Interest)

我們臨床蛋白質體實驗室主要以癌症研究為主。在台灣癌症是十大死因之首,每年超過80000人因其而犧牲,因此癌症的相關研究顯得格外重要。肺癌在台灣是導致死亡率最高的癌症(17.5%),每年約占新診斷出癌症的12.4%;口腔癌在台灣則是致死率第四高的癌症,每年超過2100人因其而犧牲。僅管過去的二十年中,肺癌與口腔癌的治療已有明顯的進步與改善,但是這些癌症病患的存活率卻不見明顯的增加,究其原因,在於病人診斷出時通常已為癌症晚期,因此治癒率甚差。以肺癌為例:五年存活率整體來說低於15%。因此若有有效的腫瘤標誌以早期診斷肺癌與口腔癌,定能改善癌症病患的治療與預後。我們實驗室致力於找尋肺癌與口腔癌的新穎腫瘤標誌,更進一步探討這些腫瘤標誌在腫瘤細胞中扮演的生物學意義。

我們實驗室主要以新穎的蛋白質體學(proteomics)技術,解析癌症的相關議題。細胞中執行生物功能的巨分子多為蛋白質,因此蛋白質的功能探討在癌症研究中是重要的一環。現今生物質譜儀(mass spectrometry)的發展,讓研究學者得以體學的角度研究蛋白質;例如:系統的觀察細胞中所有蛋白質的表現量、與巨分子的交互作用、位置與轉譯後修飾。因蛋白質體技術的優勢,此技術已被廣泛的運用於疾病之研究,特別是在體液的腫瘤生物標誌搜尋和鑑定上。我們實驗室致力於使用與發展蛋白質體學技術,以找尋新穎的疾病蛋白標誌,更以蛋白質體學技術探討這些蛋白在疾病中扮演的角色。

 

論文與著作(Publication)

最近五年所發表論文

1.   Kuo RL#, Lin YH, Wang RY, Hsu CW, Chiu YT, Huang HI, Kao LT, Yu JS, Shih SR, Wu CC#. Proteomics analysis of EV71-infected cells reveals the involvement of host protein NEDD4L in EV71 replication. J. Proteome Res. 2015, 14(4), 1818-30. (#corresponding author)

2.    Liu PJ, Chen C, Wang CL, Wu YC, Hsu CW, Lee CW, Huang LH, Yu JS, Chang YS, Wu CC#, Yu CJ#. In-depth proteomic analysis of six types of exudative pleural effusions for non-small cell lung cancer biomarker discovery. Mol. Cell. Proteomics 2015, 14(4), 917-32. (#corresponding author)

3.   Wang LJ, Huang HY, Huang MP, Liou W, Chang YT, Wu CC, Ojcius DM, Chang YS. The microtubule-associated protein EB1 links AIM2 inflammasomes with autophagy-dependent secretion. J. Biol. Chem. 2014, 289(42), 29322-33.

4.    Wang LJ, Wu CC, Lee SY, Tsai YF. Salivary neurosteroid levels and behavioural profiles of children with attention-deficit/hyperactivity disorder during six months of methylphenidate treatment. J. Child Adolesc. Psychopharmacol. 2014, 24 (6), 336-40.

5.     Hsu CW, Yu JS, Peng PH, Liu SC, Chang YS, Chang KP, Wu CC. Secretome profiling of primary cells reveals that THBS2 is a salivary biomarker of oral cavity squamous cell carcinoma. J. Proteome Res. 2014, 13(11), 4796-807.

6.     Chen CD, Wang CL, Yu CJ, Chien KY, Chen YT, Chen MC, Chang YS, Wu CC#, Yu JS#. Targeted proteomics pipeline reveals potential biomarkers for the diagnosis of metastatic lung cancer in pleural effusion. J. Proteome Res. 2014, 13(6), 2818-29. (#corresponding author)

7.    Wu CC, Chang YT, Chang KP, Liu YL, Liu HP, Lee IL, Yu JS, Chiang WF. Salivary auto-antibodies as noninvasive diagnostic markers of oral cavity squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 2014, 23(8), 1569-78.

8.   Yeh YM, Chen CY, Huang PR, Hsu CW, Wu CC#, Wang TC#. Proteomic analyses of genes regulated by heterogeneous nuclear ribonucleoproteins A/B in Jurkat cells. Proteomics 2014, 14(11), 1357-66. (#corresponding author)

9.      Chen CC, Liu HP, Chao M, Liang Y, Tsang NM, Huang HY, Wu CC, Chang YS. NF-kB-mediated transcriptional upregulation of TNFAIP2 by the Epstein-Barr virus oncoprotein, LMP1, promotes cell motility in nasopharyngeal carcinoma. Oncogene 2014, 33(28), 3648-59.

10.  Lin HR*, Wu CC*,#, Wu YH, Hsu CW, Cheng ML, Chiu DT. Proteome-wide dysregulation by glucose-6-phosphate dehydrogenase (G6PD) reveals a novel protective role for G6PD in aflatoxin B1-mediated cytotoxicity. J. Proteome Res. 2013, 12(7), 3434-48. (*equal contribution, #corresponding author)

11.  Chen CL, Lin TS, Tsai CH, Wu CC, Chung T, Chien KY, Wu M, Chang YS, Yu JS, Chen YT. Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics. J. Proteomics 2013, 85, 28-43.

12.  Chang KP, Wu CC, Fang KH, Tsai CY, Chang YL, Liu SC, Kao HK. Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and treatment outcome in patients with oral cavity squamous cell carcinoma. Oral Oncol. 2013, 49(8), 802-7.

13.  Chang KP, Kao HK, Wu CC, Fang KH, Chang YL, Huang YC, Liu SC, Cheng MH. Pretreatment interleukin-6 serum levels are associated with patient survival for oral cavity squamous cell carcinoma. Otolaryngol. Head Neck Surg. 2013, 148(5), 786-91.

14.  Chang YF, Yu JS, Chang YT, Su LC, Wu CC, Chang YS, Lai CS, Chou C. The utility of a high-throughput scanning biosensor in the detection of the pancreatic cancer marker ULBP2. Biosens. Bioelectron. 2013, 41(1), 232-7.

15.  Wang LJ, Hsu CW, Chen CC, Liang Y, Chen LC, Ojcius DM, Tsang NM, Hsueh C, Wu CC#, Chang YS#. Interactome-wide analysis identifies end-binding protein 1 as a crucial component for the speck-like particle formation of activated AIM2 inflammasomes. Mol. Cell. Proteomics 2012, 11(11), 1230-44. (#corresponding author)

16.  Tsai MH, Wu CC, Peng PH, Liang Y, Hsiao YC, Chien KY, Chen JT, Lin SJ, Tang RP, Hsieh LL, Yu JS. Identification of secretory gelsolin as a plasma biomarker associated with distant organ metastasis of colorectal cancer. J. Mol. Med. 2012, 90(2), 187-200.

17.  Liu HP, Chen CC, Wu CC, Huang YC, Liu SC, Liang Y, Chang KP, Chang YS. Epstein-Barr Virus-Encoded LMP1 Interacts with FGD4 to Activate Cdc42 and Thereby Promote Migration of Nasopharyngeal Carcinoma Cells. PLoS Pathog. 2012, 8(5), e1002690.

18.  Hsu CC, Lee YC, Yeh SH, Chen CH, Wu CC, Wang TY, Chen YN, Hung LY, Liu YW, Chen HK, Hsiao YT, Wang WS, Tsou JH, Tsou YH, Wu MH, Chang WC, Lin DY. 58-kDa microspherule protein (MSP58) is novel Brahma-related gene 1 (BRG1)-associated protein that modulates p53/p21 senescence pathway. J. Biol. Chem. 2012, 287(27), 22533-48.

19.  Chen YT, Chen HW, Domanski D, Smith DS, Liang KH, Wu CC, Chen CL, Chung T, Chen MC, Chang YS, Parker CE, Borchers CH, Yu JS. Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. J. Proteomics 2012, 75(12), 3529-45.

20.  Chen CL, Lai YF, Tang P, Chien KY, Yu JS, Tsai CH, Chen HW, Wu CC, Chung T, Hsu CW, Chen CD, Chang YS, Chang PL, Chen YT. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J. Proteome Res. 2012, 11(12), 5611-29.

21.  Yu CJ, Wang CL, Wang CI, Chen CD, Dan YM, Wu CC, Wu YC, Lee IN, Tsai YH, Chang YS, Yu JS. Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology. J. Proteome Res. 2011, 10(10), 4671-82.

22.  Yu CJ, Chang KP, Chang YJ, Hsu CW, Liang Y, Yu JS, Chi LM, Chang YS, Wu CC. Identification of guanylate-binding protein 1 as a potential oral cancer marker involved in cell invasion using omics-based analysis. J. Proteome Res. 2011, 10(8), 3778-88.

23.  Wang LJ, Huang YS, Hsiao CC, Chiang YL, Wu CC, Shang ZY, Chen CK. Salivary dehydroepiandrosterone, but not cortisol, is associated with attention deficit hyperactivity disorder. World J. Biol. Psychiatry 2011, 12(2), 99-109.

24.  Wang LJ, Hsiao CC, Huang YS, Chiang YL, Ree SC, Chen YC, Wu YW, Wu CC, Shang ZY, Chen CK. Association of salivary dehydroepiandrosterone levels and symptoms in patients with attention deficit hyperactivity disorder during six months of treatment with methylphenidate. Psychoneuroendocrinology 2011, 36(8), 1209-16.

25.  Wang CI, Wang CL, Wang CW, Chen CD, Wu CC, Liang Y, Tsai YH, Chang YS, Yu JS, Yu CJ. Importin subunit alpha-2 is identified as a potential biomarker for non-small cell lung cancer by integration of the cancer cell secretome and tissue transcriptome. Int. J. Cancer 2011, 128(10), 2364-72.

26.  Peng PH, Wu CC#, Liu SC, Chang KP, Chen CD, Chang YT, Hsu CW, Chang YS, Yu JS#. Quantitative plasma proteome analysis reveals aberrant level of blood coagulation-related proteins in nasopharyngeal carcinoma. J. Proteomics 2011, 74(5), 744-57. (#corresponding author)

27.  Liu HP*, Wu CC*, Kao HY, Huang YC, Liang Y, Chen CC, Yu JS, Chang YS. Proteome-wide dysregulation by PRA1 depletion delineates a role of PRA1 in lipid transport and cell migration. Mol. Cell. Proteomics 2011, 10(3), M900641MCP200. (*equal contribution)

28.  Chang YT, Wu CC#, Shyr YM, Chen TC, Hwang TL, Yeh TS, Chang KP, Liu HP, Liu YL, Tsai MH, Chang YS, Yu JS#. Secretome-Based Identification of ULBP2 as a Novel Serum Marker for Pancreatic Cancer Detection. PloS One 2011, 6(5), e20029. (#corresponding author)

29.  Chang KP, Chang YT, Wu CC, Liu YL, Chen MC, Tsang NM, Hsu CL, Chang YS, Yu JS. Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck 2011, 33(6), 886-97.

30.  Chang KP, Chang YT, Liao CT, Yen TC, Chen IH, Chang YL, Liu YL, Chang YS, Yu JS#, Wu CC#. Prognostic cytokine markers in peripheral blood for oral cavity squamous cell carcinoma identified by multiplexed immunobead-based profiling. Clin. Chim. Acta 2011, 412(11-12), 980-7. (#corresponding author)

專利

1.  余兆松、張雅婷、吳治慶、石宜銘、張玉生。胰臟癌之血清生物檢測標誌及其應用(A serological marker for detecting pancreatic cancer and a method for using the serological marker)。中華民國專利發明第I408370號,專利權期間: 2013/9/11~2031/5/18

專書論文

  1. Wu CC, Chang YS, Chow KP. The immunogenicity of tumor cells that express Epstein-Barr virus encoded LMP1 isolated from NPC in immunocompetent mice. The 10th international congress of immunology. 1998, 1257-1261, India.
  2. Chen YT, Parker CE, Chen HW, Chen CL, Domanski D, Smith DS, Wu CC, Chung T, Liang KH, Chen MC, Chang YS, Borchers CH, Yu JS. Chapter 10: A Pipeline that Integrates the Discovery and Verification Studies of Urinary Protein Biomarkers Reveals Candidate Markers for Bladder Cancer in Comprehensive Biomarker Discovery and Validation for Clinical Application. Peter Horvatovich, ‎Rainer Bischoff, ‎David E. Thurston (Editors), Royal Society of Chemistry (RSC), 2013.